In a recent case series of patients with prostate cancer, a high proportion of ATM gene variants were present in plasma attributable to CHIP, impacting the ability to identify patients eligible for PARP inhibitors and the association with clinical efficacy [96]. The gene discussed is STUB1; the disease is prostate carcinoma.